N-Substituted Aryl Oligomer Propionamides for Reduced CNS Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticonvulsant 3-alkoxypropionamides used in treating epilepsy and neuropathic pain are associated with significant side effects such as vertigo, diplopia, blurred vision, nausea, vomiting, dizziness, ataxia, and tremor, highlighting a need for novel compounds with improved pharmacology and reduced adverse effects.
Innovation Solution
Development of N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides, where a 3-alkoxypropionamide residue is covalently attached via a carbamate linkage to a water-soluble, non-peptidic oligomer, enhancing therapeutic efficacy while minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional 3-alkoxypropionamides are used for treating epilepsy and neuropathic pain, then therapeutic efficacy is achieved, but significant side effects occur including vertigo, diplopia, blurred vision, nausea, vomiting, dizziness, ataxia, and tremor
Solution Approach 1:
The patent applies segmentation by dividing the conventional 3-alkoxypropionamide molecule into two distinct components: the active pharmacological residue and a water-soluble oligomer carrier. This segmentation allows the active residue to maintain therapeutic efficacy while the oligomer carrier reduces blood-brain barrier penetration, thereby minimizing side effects associated with CNS exposure
Solution Approach 2:
The patent employs an intermediary approach by introducing a water-soluble oligomer as a carrier molecule that mediates between the lipophilic active residue and the aqueous biological environment. This intermediary carrier reduces the compound's ability to penetrate the blood-brain barrier through hydrophilic interactions, thereby decreasing harmful CNS side effects while maintaining peripheral therapeutic activity
2Reliability
If conventional 3-alkoxypropionamides are administered, then seizure control is achieved, but pharmacological profile is limited by adverse effects
Solution Approach 1:
The patent applies parameter changes by systematically modifying the hydrophilicity parameter of the 3-alkoxypropionamide compounds through attachment to water-soluble oligomers of varying molecular weights and structures. This parameter change transforms the pharmacological profile from highly lipophilic (with significant CNS penetration and side effects) to hydrophilic (with reduced CNS penetration and improved safety profile), while maintaining the essential therapeutic activity
3Reliability
If lipophilic 3-alkoxypropionamides are used to maintain bioavailability, then therapeutic activity is preserved, but blood-brain barrier penetration causes adverse effects
Solution Approach 1:
The patent applies local quality by creating a heterogenous molecular structure where different regions of the compound have opposite solubility characteristics: the active residue maintains lipophilic properties necessary for therapeutic binding and activity, while the oligomer carrier provides hydrophilic properties that reduce blood-brain barrier penetration. This local differentiation of quality allows simultaneous achievement of therapeutic efficacy and reduced CNS side effects
Data Source
Figure 1
Figure 2
AI summary
The invention relates to (among other things) N-optionally substituted aryl- 2-oligomer-3-alkoxypropionamides and compositions comprising the same. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.